Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Curr Hematol Malig Rep. 2017 Aug;12(4):344–357. doi: 10.1007/s11899-017-0397-7

Table 2.

Design of BCMA targeted CAR T cell vectors and clinical trials for MM

Institution NCI Bluebird Multi-Inst Nanjing Legend UPenn MSK
Overview graphic file with name nihms900667t1.jpg graphic file with name nihms900667t2.jpg graphic file with name nihms900667t3.jpg graphic file with name nihms900667t4.jpg graphic file with name nihms900667t5.jpg
scFv derived from Murine Hybridoma Murine Hybridoma Murine Hybridoma Human Library Human Library
Co-stimulatory domain CD28 4-1BB 4-1BB 4-1BB 4-1BB
Gene transfer Retrovirus Lentivirus Lentivirus Lentivirus Retrovirus
Conditioning Cyclophosphamide+ Fludarabine Cyclophosphamide+ Fludarabine Cyclophosphamide None (cohort 1)> Cyclophosphamide Cyclophosphamide+/-Fludarabine
BCMA Ag required >50% >50% “clear expression” no requirement >1%
Clinicaltrials.gov Identifier NCT02215967 NCT02658929 NCT03090659 NCT02546167 NCT03070327
Median prior lines 7 7 3 9 Not yet reported
Efficacy CR: 1 CR: 4 CR: 15 CR: 1 Not yet reported
VGPR: 4 VGPR: 7 VGPR: 13 VGPR: 2
PR: 3 PR: 4 PR: 7 PR: 1
16 evaluable pts 18 evaluable pts 35 evaluable pts 9 evaluable pts
Legend graphic file with name nihms900667t6.jpg

NCI National Cancer Institute, UPenn University of Pennsylvania, MSK Memorial Sloan Kettering, scFv single chain variable fragment, CD3 ζ T cell receptor zeta-chain